Biotech IPO first-day trading showed pressure as Bambusa Therapeutics and Aspen Neuroscience opened below their offering prices amid a broader NASDAQ sell-off. The public-equity update reported double-digit declines for both names during Friday’s session, though each recovered part of the drop before the close. The coverage tied market weakness to a combination of macro factors and concerns about AI-company valuations alongside disappointing earnings weighing on the index. The episode highlights how capital-market conditions can quickly override company-specific fundamentals during early trading. For biotech issuers, the immediate post-IPO trading window is increasingly sensitive to index-level volatility, which can affect follow-on financing leverage and liquidity perception.